PARIS — Sanofi has gained Food and Drug Administration approval for Adlyxin (lixisenatide), a medication for type 2 diabetes. A once-daily mealtime GLP-1 receptor agonist injection, Adlyxin is indicated as an adjunct to diet and exercise for improving blood glucose control in the treatment of adults with type 2 diabetes.Sanofi said this week that Adlyxin
PARIS — Sanofi has agreed to a 22.8 billion euro ($25.1 billion) asset swap with Germany’s Boehringer Ingelheim GmbH that will boost the French drug manufacturer’s business in selling over-the-counter drugs. The two companies reached a definitive agreement late Monday after announcing exclusive negotiations in December. Terms are unchanged from the original announcement: Sanofi will
NEW YORK — Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.45 billion U.S.), and Boehringer Ingelheim’s consumer health care business,valued at €6.7 billion ($7.32 billion U.S.).
PARIS and MOUNTAIN VIEW, Calif. — Sanofi and the life sciences team at Google have formed a collaboration to improve care and outcomes for people with type 1 and type 2 diabetes. The companies said the alliance will pair Sanofi’s leadership in diabetes treatments and devices with Google’s expertise in analytics, miniaturized electronics and low-power chip
